Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oleg Gluz

Showing results (61-70 of 97) with videos related to

Pageof 10
Sort By:
JAMA Oncology|May 11, 2023
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical TrialOleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 TrialMonika Graeser, Oleg Gluz, Peter Schmid, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 19, 2024
Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis: Recommendations From the European Lobular Breast Cancer ConsortiumMaxim De Schepper, Thijs Koorman, François Richard, et al.
Cancer Medicine|November 15, 2021
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancerIsabel Grote, Stephan Bartels, Leonie Kandt, et al.
International Journal of Cancer|February 3, 2021
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrialsMonika Graeser, Simone Schrading, Oleg Gluz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2017
De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ETNadia Harbeck, Oleg Gluz, Matthias Christgen, et al.
Molecular Cancer|March 27, 2025
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trialDarren Korbie, Clare Stirzaker, Oleg Gluz, et al.
Therapeutic Advances in Medical Oncology|December 7, 2020
The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancerUlrike Nitz, Oleg Gluz, Hans H Kreipe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2022
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN TrialOleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, et al.
Journal of the National Cancer Institute|December 12, 2017
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial ResultsOleg Gluz, Ulrike Nitz, Cornelia Liedtke, et al.
Pageof 10

Showing results (61-70 of 97) with videos related to

Sort By:
Pageof 10
JAMA Oncology|May 11, 2023
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical TrialOleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 TrialMonika Graeser, Oleg Gluz, Peter Schmid, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 19, 2024
Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis: Recommendations From the European Lobular Breast Cancer ConsortiumMaxim De Schepper, Thijs Koorman, François Richard, et al.
Cancer Medicine|November 15, 2021
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancerIsabel Grote, Stephan Bartels, Leonie Kandt, et al.
International Journal of Cancer|February 3, 2021
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrialsMonika Graeser, Simone Schrading, Oleg Gluz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2017
De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ETNadia Harbeck, Oleg Gluz, Matthias Christgen, et al.
Molecular Cancer|March 27, 2025
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trialDarren Korbie, Clare Stirzaker, Oleg Gluz, et al.
Therapeutic Advances in Medical Oncology|December 7, 2020
The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancerUlrike Nitz, Oleg Gluz, Hans H Kreipe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2022
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN TrialOleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, et al.
Journal of the National Cancer Institute|December 12, 2017
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial ResultsOleg Gluz, Ulrike Nitz, Cornelia Liedtke, et al.
Pageof 10